{
    "nctId": "NCT06405269",
    "briefTitle": "A Multicentre Prospective Cohort Study: Effect of (Neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients",
    "officialTitle": "A Multicentre Prospective Cohort Study: Effect of (Neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Young Breast Cancer Patient, Lipids, Anti-tumour Drug Therapy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 600,
    "primaryOutcomeMeasure": "Proportion of patients who developed LDL-C abnormalities in 3 groups",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* ECOG score 0-1\n* Resectable breast cancer\n* No distant metastases on postoperative imaging assessment\n* Patients proposed for (neo)adjuvant therapy\n* No previous oral lipid-lowering drugs, serum LDL-C level within normal range, i.e. LDL-C value: \\&lt;3.4 mmol/L\n* No fatty liver by liver ultrasound/CT examination\n* No major organ dysfunction\n\nExclusion Criteria:\n\n* Patients with pre-existing hyperlipidaemia, coronary heart disease, fatty liver disease, or who have received or are receiving lipid-lowering medication\n* Enrolled in another study or less than or equal to 4 weeks since discontinuation of other medications\n* Presence of severe dysfunction of vital organs\n* Patients with other malignancies (except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumours that have been cured for at least 5 years)\n* Acute infectious diseases or chronic infectious diseases in active stage\n* History of uncontrolled epilepsy, central nervous system disease or mental disorder",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}